AstraZeneca PLC (AZN)
162.13
-0.57
(-0.35%)
USD |
NYSE |
Aug 31, 16:00
159.64
-2.49
(-1.54%)
Pre-Market: 04:58
AstraZeneca Cash from Operations (TTM) : 14.54B for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 14.54B |
| December 31, 2025 | 14.90B |
| September 30, 2025 | 15.46B |
| June 30, 2025 | 13.72B |
| March 31, 2025 | 13.40B |
| December 31, 2024 | 12.20B |
| September 30, 2024 | 11.69B |
| June 30, 2024 | 11.42B |
| March 31, 2024 | 10.01B |
| December 31, 2023 | 10.63B |
| September 30, 2023 | 10.60B |
| June 30, 2023 | 10.36B |
| March 31, 2023 | 9.833B |
| December 31, 2022 | 9.868B |
| September 30, 2022 | 8.86B |
| June 30, 2022 | 7.634B |
| March 31, 2022 | 7.274B |
| December 31, 2021 | 5.997B |
| September 30, 2021 | 6.375B |
| June 30, 2021 | 6.483B |
| March 31, 2021 | 6.637B |
| December 31, 2020 | 4.846B |
| September 30, 2020 | 4.436B |
| June 30, 2020 | 3.746B |
| March 31, 2020 | 3.611B |
| Date | Value |
|---|---|
| December 31, 2019 | 3.093B |
| September 30, 2019 | 3.967B |
| June 30, 2019 | 3.328B |
| March 31, 2019 | 2.567B |
| December 31, 2018 | 2.810B |
| September 30, 2018 | 1.587B |
| June 30, 2018 | 3.374B |
| March 31, 2018 | 3.501B |
| December 31, 2017 | 3.742B |
| September 30, 2017 | 4.694B |
| June 30, 2017 | 3.248B |
| March 31, 2017 | 3.167B |
| December 31, 2016 | 4.257B |
| September 30, 2016 | 2.854B |
| June 30, 2016 | 3.802B |
| March 31, 2016 | 4.702B |
| December 31, 2015 | 3.447B |
| September 30, 2015 | 4.735B |
| June 30, 2015 | 4.925B |
| March 31, 2015 | 5.943B |
| December 31, 2014 | 7.198B |
| September 30, 2014 | 7.829B |
| June 30, 2014 | 7.018B |
| March 31, 2014 | 6.519B |
| December 31, 2013 | 7.477B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| GSK Plc | 10.64B |
| Johnson & Johnson | 27.61B |
| Eli Lilly & Co. | 28.08B |
| Merck & Co., Inc. | 19.97B |
| Novo Nordisk A/S | 20.59B |